Cubist Pharmaceuticals Inc news

   Watch this stock
Showing stories 1 - 10 of about 100   

Articles published

CBST 72.61 +0.11 (0.15%)
price chart
New Cubist Pharmaceuticals chief executive will be Robert J. Perez
Cubist Pharmaceuticals Inc. said Monday it plans to install a new chief executive, a surprise move that raised questions about whether the Lexington company will keep expanding as the leading US maker of antibiotics or become a takeover target.
Cubist Pharmaceuticals Names Robert J. Perez Chief Executive Officer  MarketWatch
Cubist's next CEO foresees 'evolution, not revolution' for the ...  Boston Business Journal (blog)
Related articles »  
Cubist Pharmaceuticals Inc's Momentum Builds As Anti-Infection Product Line ...
Last year, Cubist acquired Dificid when it bought Optimer Pharmaceuticals for $551 million, and Dificid's sales total $47.7 million through the first nine months of 2014.
Cubist Pharmaceuticals Breaks Above 200-Day Moving Average - Bullish for CBST  Nasdaq
Cubist Pharmaceuticals Q3 Earnings Beat Expectations  Zacks.com
Related articles »  
Morningstar Issues BBB- Credit Rating to Cubist Pharmaceuticals (CBST)
Cubist Pharmaceuticals logo Cubist Pharmaceuticals (NASDAQ:CBST) has earned a �BBB-� credit rating from analysts at Morningstar.
Trend Analysis Report- CDK Global Inc (NASDAQ:CDK), Cubist ...  Techsonian (press release)
Hot Watch List : Cubist Pharmaceuticals (NASDAQ:CBST), Cerus Corporation ...  Gaining Green
Related articles »  
Investor's Alert- Cubist Pharmaceuticals Inc (NASDAQ:CBST), Rite Aid ...
Las Vegas, NV �October 27, 2014� (TechSonian) - Cubist Pharmaceuticals Inc (NASDAQ:CBST) revealed its financial position that thenet product revenues increased 12% to $256.7 million from $229.9 million in Q3 2013, the first quarter with U.S.
Related articles »  
Cubist Pharmaceuticals EVP Unloads $3146894 in Stock (CBST)
Cubist Pharmaceuticals logo Cubist Pharmaceuticals (NASDAQ:CBST) EVP Steven C. Gilman sold 48,125 shares of the company's stock in a transaction that occurred on Wednesday, October 1st. The stock was sold at an average price of $65.39, for a total ...
Related articles »  
Why Need to Watch: Cubist Pharmaceuticals Inc. (NASDAQ:CBST), Heat ...
Cubist Pharmaceuticals Inc. (NASDAQ:CBST) EVP Steven C. Gilman sold 48,125 shares of the company's stock in a transaction that occurred on Wednesday, October 1st.
Morningstar Assigns BBB- Credit Rating to Cubist Pharmaceuticals (CBST)
Cubist Pharmaceuticals logo Cubist Pharmaceuticals (NASDAQ:CBST) has received a �BBB-� credit rating from analysts at Morningstar.
Cubist Pharmaceuticals (CBST) Releases Quarterly Earnings Results, Beats ...
Cubist Pharmaceuticals logo Cubist Pharmaceuticals (NASDAQ:CBST) released its earnings data on Tuesday. The company reported $0.58 earnings per share for the quarter, beating the analysts' consensus estimate of $0.04 by $0.54, ...
Related articles »  
Morningstar Gives "BBB-" Credit Rating to Cubist Pharmaceuticals (CBST)
Cubist Pharmaceuticals logo Cubist Pharmaceuticals (NASDAQ:CBST) has been given a �BBB-� credit rating by Morningstar.
Stocks to Track �Cubist Pharmaceuticals Inc (NASDAQ:CBST), ManpowerGroup ...  Techsonian (press release)
Related articles »  
News Buzz: Zynga Inc (NASDAQ:ZNGA), Cubist Pharmaceuticals Inc. (NASDAQ ...
Cubist Pharmaceuticals Inc. (NASDAQ:CBST) announced that it will present new data from its antibiotics portfolio at IDWeek 2014, October 8-12, in Philadelphia, PA.